Springthorpe B, Bailey A, Barton P, From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007; 17 (21): 6013-6018. doi: 10.1016/j.bmcl.2007.07.057 17827008
Wallentin L, Becker RC, Budaj A,; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 (11): 1045-1057. doi: 10.1056/NEJMoa0904327 19717846
Storey RF, James SK, Siegbahn A, Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014; 25 (7): 517-525. doi: 10.3109/09537104.2013.842965 24127651
Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010; 38 (9): 1514-1521. doi: 10.1124/dmd.110.032250 20551239
Nishimura RA, Otto CM, Bonow RO, 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135 (25): e1159-e1195. doi: 10.1161/CIR.0000000000000503 28298458
